Introduction to symposium on vascular biology, metabolism and cancer
Lena Claesson-Welsh
págs. 112-113
VEGFA and tumour angiogenesis
Lena Claesson-Welsh, Michael J. Welsh
págs. 114-127
Anti-angiogenesis and metastasis: a tumour and stromal cell alliance
L. Moserle, O. Casanovas
págs. 128-137
Class 3 semaphorins: physiological vascular normalizing agents for anti-cancer therapy
G. Serini, F. Bussolino, F. Maione
págs. 138-155
Endothelial cell metabolism and tumour angiogenesis: glucose and glutamine as essential fuels and lactate as the driving force
F. Polet, Olivier Feron
págs. 156-165
Genetically engineered T cells for the treatment of cancer
M. Essand, A. S. I. Loskog
págs. 166-181
Assessing patients with myocardial infarction and nonobstructed coronary arteries (MINOCA)
JohnF. Beltrame
págs. 182-185
Can treatment of the skin rescue the heart?
Mona Ståhle
págs. 186-188
Myocardial infarction with normal coronary arteries is common and associated with normal findings on cardiovascular magnetic resonance imaging: results from the Stockholm Myocardial Infarction with Normal Coronaries study
O. Collste, P. Sörensson, M. Frick
págs. 189-196
Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study
Ole Ahlehoff, Lone Skov, Gunnar H. Gislason
págs. 197-204
The inflammatory biomarker YKL-40 at admission is a strong predictor of overall mortality
Niels Mygind, A. K. Iversen, Lars Kober
págs. 205-216
Response to comment from Dr. Sloan: ‘Look what's going down’
R. P. Nolan, John S. Floras, L. Ahmed
págs. 217-218
© 2001-2024 Fundación Dialnet · Todos los derechos reservados
Coordinado por: